The peripheral cannabinoid receptor Cb2, frequently expressed on AML blasts, either induces a neutrophilic differentiation block or confers abnormal migration properties in a ligand-dependent manner by Alberich-Jorda, M. (Meritxell) et al.
NEOPLASIA
The peripheral cannabinoid receptor Cb2, frequently expressed on AML blasts,
either induces a neutrophilic differentiation block or confers abnormal
migration properties in a ligand-dependent manner
Meritxell Alberich Jorda`, Nazik Rayman, Marjolein Tas, Sandra E. Verbakel, Natalia Battista, Kirsten van Lom, Bob Lo¨wenberg,
Mauro Maccarrone, and Ruud Delwel
Cb2, the gene encoding the peripheral
cannabinoid receptor, is located in a com-
mon virus integration site and is overex-
pressed in retrovirally induced murine
myeloid leukemias. Here we show that
this G protein–coupled receptor (GPCR)
is also aberrantly expressed in a high
percentage of human acute myeloid leuke-
mias. We investigated the mechanism of
transformation by Cb2 and demonstrate
that aberrant expression of this receptor
on hematopoietic precursor cells results
in distinct effects depending on the li-
gand used. Cb2-expressing myeloid pre-
cursors migrate upon stimulation by the
endocannabinoid 2-arachidonoylglycerol
and are blocked in neutrophilic differentia-
tion upon exposure to another ligand,
CP55940. Both effects depend on the
activation of Gi proteins and require the
mitogen-induced extracellular kinase/ex-
tracellular signal-regulated kinase (MEK/
ERK) pathway. Down-regulation of cyclic
adenosine monophosphate (cAMP) lev-
els upon Gi activation is important for
migration induction but is irrelevant for
the maturation arrest. Moreover, the highly
conserved G protein–interacting DRY mo-
tif, present in the second intracellular
loop of GPCRs, is critical for migration
but unimportant for the differentiation
block. This suggests that the Cb2-medi-
ated differentiation block requires interac-
tion of Gi proteins with other currently
unknown motifs. This indicates a unique
mechanism by which a transforming
GPCR, in a ligand-dependent manner,
causes 2 distinct oncogenic effects: al-
tered migration and block of neutrophilic
development. (Blood. 2004;104:526-534)
© 2004 by The American Society of Hematology
Introduction
Using retroviral insertional mutagenesis we recently demonstrated
that Cb2, the gene encoding the peripheral cannabinoid receptor, is
located in a common virus integration site (Evi11) in Cas-Br-M
murine leukemia virus (MuLV)–induced myeloid leukemias, sug-
gesting that Cb2 is a protooncogene involved in transformation.1,2
Cb2 encodes a 7-transmembrane (7TM) protein belonging to the
family of Gi protein–coupled receptors (GiPCRs).3 This receptor
is normally expressed in areas enriched for B lymphocytes—that is,
marginal zone of the spleen, in the cortex of lymph nodes, in the
nodular corona of Peyer patches, and in the mantle zones of
secondary follicles in tonsils.3-6 Cb2 receptor is involved in B-cell
differentiation and migration of splenic B lymphocytes, suggesting
a role for this receptor in the immune response.5,7 The natural
activator of Cb2 has been demonstrated to be 2-arachidonoylglyc-
erol (2-AG),7-11 although a number of alternative Cb2 ligands have
been reported (reviewed by Howlett et al12).
Acute myeloid leukemia (AML) is characterized by an
accumulation of immature nonfunctional cells in the bone
marrow and blood.13 Myeloid leukemia is considered to be a
multigenetic disease involving cooperation between several
disease genes.14-16 The genetic abnormalities in AML may result
in aberrant expression of protooncogenes or inactivation of
tumor suppressor genes, and consequently leukemia cells escape
from regulatory signals, resulting in altered proliferation, aber-
rant survival, and a maturation arrest. Our previous observation
that Cb2 is overexpressed in myeloid cell lines containing a
retroviral insertion near Cb2 suggests that it may be involved in
leukemic transformation in certain mouse leukemias. In the
present study we demonstrate that the CB2 receptor is aberrantly
expressed in several human myeloid cell lines and primary AML
samples, whereas normal bone marrow precursor cells do not
express this G protein–coupled receptor (GPCR).
We generated a Cb2-EGFP fusion construct,17 which was
introduced into murine normal bone marrow cells and into
32D/granulocyte colony-stimulating factor receptor (G-CSF-R)
cells. 32D/G-CSF-R cells proliferate in vitro in the presence of
interleukin-3 (IL-3) and are capable of terminally differentiating
toward mature neutrophils upon G-CSF stimulation. Furthermore,
this cell line is a useful in vitro model to study molecular
mechanisms involved in granulocytic differentiation18-20 and to
perform functional analysis of transforming genes causing a block
of neutrophilic differentiation.17,21 The Cb2-EGFP fusion protein
appears fully functional, because the Cb2-expressing marrow cells
and 32D/G-CSF-R/Cb2 cells migrate in response to the endocan-
nabinoid 2-AG. In the present study we assessed whether 2-AG
was capable of inducing a neutrophilic differentiation block of
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32D/G-CSF-R/Cb2 cells. We demonstrate that the endocannabi-
noid 2-AG, although being a potent stimulator of migration of
Cb2-expressing cells, could not block G-CSF–induced neutrophilic
differentiation. Next, we tested whether another potent cannabinoid
ligand, CP55940,22,23 could affect neutrophilic differentiation of Cb2-
expressing cells. Interestingly, CP55940 failed to induce migration but
evoked a complete arrest of neutrophilic differentiation.
Classical signaling by GPCRs is based on transduction of
extracellular signals to downstream effectors via intracellular,
heterotrimeric G protein complexes, which comprise , , and 
subunits.24,25 The recruitment of G proteins to GPCRs may require
several motifs present in 7TM receptors. A well-characterized
domain involving G protein recruitment and activation is the
so-called DRY motif.26-29 The DRY (Asp-Arg-Tyr) box is a highly
conserved region in 7TM receptors, located N-terminally in the
second intracellular loop of most GPCRs. To analyze whether the
DRY motif present in Cb2 receptor is crucial for migration and/or
block of differentiation, we generated 2 different DRY mutants,
DRA-Cb2 and DAY-Cb2. Finally, we demonstrated that mitogen-
induced extracellular kinase/extracellular signal-regulated kinase
(MEK/ERK) signaling is involved in both Cb2 functions whereas
down-regulation of the intracellular cAMP levels is only required
for migration.
Materials and methods
Cannabinoid ligands, cytokines, and inhibitors
of intracellular signaling
The Cb2 ligands 2-arachidonoylglycerol (2-AG), anandamide (AEA), WIN
55212-2, cannabinol, cannabidiol, 8-tetrahydrocannabinol (8-THC), and
9-tetrahydrocannabinol (9-THC) were obtained from Sigma (Zwijn-
drecht, The Netherlands). N-palmitoylethanolamine (PEA) and N-
acylethanolamine (POEA) were from ICN Biomedicals (Zoetermeer, The
Netherlands) and CP55940 from Pfizer (Groton, CT). Cb1 inverse agonist
SR141716 and Cb2 inverse agonist SR144528 were kindly donated by Dr
Casellas (Sanofi Recherche, Montpellier, France). Recombinant human
stromal cell-derived factor-1 (SDF-1) was obtained from R&D Systems
(Uithoorn, The Netherlands). Murine IL-3 was obtained from an IL-3–
producing Chinese hamster ovary (CHO) cell line, and G-CSF was from
Amgen (Thousand Oaks, CA). Dibutyryl cyclic adenosine monophosphate
(dbcAMP) and U0126 (MEK inhibitor) were from Kordia Life Sciences
(Leiden, The Netherlands) whereas PD98059 (MEK inhibitor) was ob-
tained from Omnilabo International (Breda, The Netherlands). The inhibi-
tors were dissolved in dimethyl sulfoxide (DMSO) and added to the
cultures at the indicated concentrations and were refreshed daily.
Cb2-EGFP expression construct, site-directed mutagenesis,
and infection of 32D/G-CSF-R cells
A Cb2-EGFP fusion construct was generated and cloned into pLNCX
(Clontech, Palo Alto, CA) as described previously.17 A QuikChange
Site-Directed Mutagenesis Kit was used to mutate the DRY motif present in
Cb2-EGFP receptor as indicated by the supplier (Stratagene Europe,
Amsterdam, The Netherlands). The primers 5-GCTGTTGACCGCGC-
CCTATGTCTGTG-3 and 5-CACAGACATAGGGCGCGGTCAA-
CAGC-3 were used to mutate the wild-type (wt) DRY motif into a DRA
motif, and the primers 5-CCGCTGTTGACGCCTACCTATGTCTG-3
and 5-CAGACATAGGTAGGCGTCAACAGCGG-3 were used to mutate
the wt DRY motif into a DAY motif (Figure 5). The Cb2-EGFP and the
DRY mutated constructs were verified by nucleotide sequence. These
expression constructs were transfected into Phoenix cells type E (gift from
G. Nolan, Stanford, CA), and the viral supernatants were used for infection
of 32D/G-CSF receptor (32D/G-CSF-R) cells. Single clones were obtained
using limiting dilution in 96-well microtiter trays (Becton Dickinson,
Mountain View, CA), and infected clones were selected on 0.8 mg/mL
G418 (Gibco, Breda, The Netherlands). Cb2-EGFP fusion protein and DRY
mutant expression was analyzed by Leica DMRXA microscopy (Leica
Microsystems, Rijswijk, The Netherlands) and flow cytometric analysis of
enhanced green fluorescent protein (EGFP) fluorescence.
Flow cytometric analysis
32D/G-CSF-R cells transduced with Cb2-EGFP,17 as well as with Cb2-
EGFP DRA mutant, Cb2-EGFP DAY mutant, and EGFP control, were
analyzed by flow cytometric analysis by means of EGFP (FACScan flow
cytometer; Becton Dickinson, Mountain View, CA) as described previ-
ously.17 EGFP cell fluorescence was visualized using a fluorescence
microscope (DMRXA; Leica, Wetzlar, Germany) with PL APO 63 /1.32
lenses. The images were captured with a Leica DMRXA camera, and Leica
QFISH software was used.
The myeloid cell lines HL60 (ATCC CCL 240; American Type Culture
Collection, Manassas, VA), MV 4-11 (ATCC CRL 9591), U937 (ATCC
CRL 1593), KG1 (ATCC CCL 246), KG1a (ATCC CCL 246.1), K562
(ATCC CCL 243), NB-4,30 and ME-1 31 as well as primary AML samples
and CD34 cells were used for immunofluorescence analyses. Bone
marrow AML samples at diagnosis and from healthy volunteers were
obtained after informed consent. Blasts from AML patients and healthy
bone marrow specimens were isolated from the samples by Ficoll-Hypaque
(Nygaard, Oslo, Norway) centrifugation.32 The cells were then cryopre-
served as described.33
Normal umbilical cord blood CD34 cells were purified using a magnetic cell
sorting system (MACS cell isolation kits; Miltenyi Biotec, Bergisch Gladbach,
Germany). In brief, cells were thawed, washed twice in RPMI 1640 medium
(Life Technologies, Breda, The Netherlands), and cultured in this medium
supplemented with penicillin (100 U/mL), streptomycin (100 ng/mL), and 10%
fetal calf serum (Life Technologies) for 1 hour at 37°C and 10% CO2. After
washing, cells were incubated on ice with the polyclonal N-terminal anti-CB2
antibody (1:50) (Affinity Bioreagents, Golden, CO) for 1 hour, followed by 30
minutes of incubation with the fluorescein isothiocyanate (FITC)–conjugated
secondary rabbit antibody (1:200) goat antirabbit (GAR)–FITC/immunoglobulin
G (IgG) (Nordic Immunological Laboratories, Tilburg, The Netherlands). In case
of dual staining, cells were incubated next for 30 minutes with phycoerythrin
(PE)–conjugated primary or secondary control antibodies (GAR-FITC/IgG and
IgG1 PE). CD34 PE and CD14 PE were obtained from Becton Dickinson
(Franklin Lakes, NJ), CD33 PE and IgG1 PE were from Beckman Coulter
(Fullerton, CA), and CD66 PE was obtained from CLB Laboratories (Amster-
dam, The Netherlands). Cells were washed twice with phosphate-buffered saline
(PBS), resuspended in 500 L PBS containing 0.5% bovine serum albumin
(BSA), and analyzed using a FACScan flow cytometer (Becton Dickinson,
Mountain View, CA).
Ligand binding analysis
[3H]2-AG was synthesized from 1,3-dibenzyloxy-2-propanol and [3H]ara-
chidonic acid (200 Ci/mmol [7400 GBq/mmol]; ARC, St Louis, MO), as
reported,34 and [3H]CP55940 (5-(1,1-dimethyheptyl)-2-(1R,5R-hydroxy-
2R-[3-hydroxypropyl] cyclohexyl)-phenol; 126 Ci/mmol [4662 GBq/mmol])
was from NEN DuPont de Nemours (Ko¨ln, Germany). Membrane fractions
were prepared from the different clones (100  106 per test) as reported35
and were used in rapid filtration assays with the synthetic cannabinoid
[3H]CP55940. Apparent dissociation constant (Kd) and maximum binding
(Bmax) values of [3H]CP55940 were calculated from saturation curves
through nonlinear regression analysis with the Prism 3 program (GraphPAD
Software for Science, San Diego, CA). Binding of [3H]2-AG was evaluated
with the same filtration assays used for [3H]CP55940, and apparent Kd and
Bmax values were calculated through nonlinear regression analysis of
saturation curves.35 In all experiments, unspecific binding was determined
in the presence of 10 M nonlabeled agonist. Data reported are the mean
(	 SD) of at least 3 independent determinations, each in duplicate.
Statistical analysis was performed by the nonparametric Mann-Whitney test
with the InStat 3 program (GraphPAD Software for Science).
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In vitro proliferation and neutrophilic differentiation
of 32D/G-CSF-R cells
The 32D/G-CSF receptor (32D/G-CSF-R) cell line19 was cultured in RPMI
1640 medium (Life Technologies) supplemented with penicillin (100
IU/mL), streptomycin (100 ng/mL), 10% fetal calf serum (FCS), and
human G-CSF (100 ng/mL) for 9 days. Cell counting was performed using
a CASY1/TTC cell counter (Scha¨rfe System, Reutlingen, Germany), and
the cell density was readjusted to 2  105/mL daily. Morphologic analysis
was done by microscopy on May-Gru¨nwald Giemsa–stained cytospins
(Shandon Holland, Amsterdam, The Netherlands). Images were acquired
with a telemicroscope system (Zeiss, Koln, Germany) consisting of an
Axioplan 2 microscope equipped with Plan Apo and Plan Neofluor
objectives. The proprietary Software Autocyte Link version 1.1 was run on
a personal computer equipped with an Intel Pentium class IV processor and
Windows 2000. Magnification,  40.
Migration assay
Migration assays were performed using 5 m pore size and 6.5-mm
diameter transwells (Corning Costar, Amsterdam, The Netherlands) as
previously described.7 In brief, cells were washed twice with Hanks
balanced salt solution (HBSS) medium, resuspended in 100 L migration
medium (Iscove modified Dulbecco medium [IMDM] plus 0.5% BSA), and
placed in the upper chamber of the transwells. In the lower chamber, 600
L migration medium with or without ligand was placed. After 4 hours of
incubation at 37°C and 5% CO2, the upper chamber was removed and the
numbers of migrated cells were determined using a CASY1/TTC cell
counter (Scha¨rfe System). Cb1- and Cb2-specific antagonists (100 nM)
were added to the upper chamber when tested. PD98059, U0126, and
dbcAMP were added to the cells, incubated 30 minutes at 37°C, and then
transferred to the upper well.
Cb2-EGFP retroviral vectors, virus production, and infection
of mouse bone marrow progenitor cells
Cb2-EGFP was obtained by Eco47III/NotI digestion from pEGFP-N1
vector and subcloned as a blunt fragment into HpaI site of pBabe retroviral
vector. Correct insertion of Cb2-EGFP was verified by nucleotide sequenc-
ing. The expression constructs were transfected into Phoenix cells type E
(gift from G. Nolan), and the virus-containing supernatants were used for
infection of bone marrow progenitor cells as described previously.21
Transduction efficiency was determined by fluorescence-activated cell
sorter (FACS) analysis of EGFP fluorescence. To study migration, cells
were cultured in Cell Gro medium supplemented as before plus 2.5 g/mL
puromycin (Sigma) for 4 to 5 days and then used in a migration assay. Bone
marrow suspension cultures were performed in RPMI 1640 medium
supplemented with 10% FCS, 2.5 g/mL puromycin (Sigma), and human
G-CSF (100 ng/mL). Cultures were carried out in the presence or absence
of CP55940, the Cb1 inverse agonist, the Cb2 inverse agonist, or
combinations of these agents. Cell countings were performed every 3 to 4
days, and cytospins were prepared for morphologic analysis.
Results
CB2 frequently is expressed on human acute myeloid leukemia
cells but absent on normal myeloid precursors
Cb2 is frequently targeted in retrovirally induced leukemia, result-
ing in overexpression of this receptor.1,7 To investigate whether
CB2 may be involved in human malignancies as well, we studied
expression of this receptor on malignant and normal myeloid
precursor cells using specific antibodies and flow cytometric
analysis. High receptor levels were observed in HL60, NB4 (Figure
1A), U937, and MV 4-11 (data not shown). The cell lines KG1,
KG1a, K562, and ME-1 did not show any CB2 protein expression
(data not shown). High CB2 expression was observed on AML
blasts in 14 of 30 patient samples. Two typical examples are
demonstrated in Figure 1B. Flow cytometric analysis of CD34-
purified fractions from normal bone marrow revealed no expres-
sion of CB2 on these cells (Figure 1B). Moreover, double labeling
of normal marrow cells using CB2-specific antibodies in combina-
tion with CD34, CD33, CD66, or CD14 revealed no detectable
CB2 levels on myeloid cells at any differentiation stage (Figure
1C). These data suggest that CB2 expression on myeloid leukemia
cells in humans as well as in mice is an abnormal feature.
CP55940 mediates a decrease of neutrophilic differentiation,
and 2-AG induces migration of Cb2-expressing bone
marrow precursors
To study the mechanism of transformation by this GPCR, we
introduced the Cb2 gene fused in frame to EGFP as previously
described7 into Percoll-separated normal murine bone marrow
cells. Cb2-expressing bone marrow cells migrated significantly in
response to the endocannabinoid 2-AG (Figure 2). These 2-AG–
migrated CB2-EGFP–expressing bone marrow cells when placed
in an in vitro colony assay were capable of generating high
numbers of G-CSF–, granulocyte-macrophage CSF (GM-CSF)–,
and IL-3–stimulated colonies (data not shown). 2-AG–induced
migration could be fully abolished by addition of Cb2 inverse
Figure 1. CB2 expression in human acute myeloid leukemia cells and normal myeloid precursors. (A) Flow cytometric analysis of a representative CB2-positive and a
CB2-negative myeloid cell line. Staining was performed using a CB2 N-terminal antibody followed by FITC-conjugated secondary rabbit antibody. (B) CB2 cell surface
expression analysis on primary AML patient samples and normal CD34 bone marrow cells using the CB2 N-terminal antibody. (C) Immunophenotyping of normal total bone
marrow using flow cytometric analysis.
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agonists, whereas Cb1 inverse agonist did not affect migration.
EGFP control–infected bone marrow cells weakly migrated upon
2-AG stimulation. The low numbers of 2-AG–migrated EGFP-
expressing control cells were not capable of forming any colonies
in vitro. Although we did not investigate which cell types were
2-AG responsive, our previous data7 would suggest that these cells
may be B lymphocytes.
In vitro culture using IL-3 or G-CSF revealed no effect of 2-AG
on proliferation or differentiation of Cb2-expressing marrow cells
(data not shown). We next studied whether another well-known
Cb2 agonist, CP55940, had an effect on marrow precursors
expressing Cb2. A decrease in neutrophilic differentiation, al-
though statistically not significant (analysis of variance [ANOVA]
test, P 
 .11), of Cb2-expressing cells was observed when cultured
in suspension with G-CSF plus CP55940 as compared with
cultures with G-CSF only (Table 1). Moreover, addition of Cb2
inverse agonist recovered the appearance of mature neutrophils
(Table 1), whereas the Cb1 inverse agonist had no effects (data not
shown). EGFP-transduced bone marrow cells do not show any
response to CP55940 or inverse agonists in an in vitro differentia-
tion assay (Table 1).
The endocannabinoid 2-AG stimulates migration, and CP55940
induces a full block of neutrophilic differentiation of
Cb2-expressing 32D/G-CSF-R cells
To further analyze the effects of Cb2 and the distinct ligands in
detail, Cb2-EGFP or EGFP constructs were introduced into 32D/G-
CSF-R cells. Eight Cb2-expressing clones and 8 EGFP control
clones were first cultured in the presence of G-CSF and different
concentrations of 2-AG (100 nM to 1 M). 2-AG did not affect
neutrophilic differentiation at any of the concentrations tested
(Figure 3A-B). On the other hand, 2-AG was shown to be an
efficient stimulator of migration of the 32D/G-CSF-R/Cb2 cells as
determined in a transwell assay (Figure 3A). This effect was
receptor specific, because 2-AG–induced migration was fully
counteracted by the Cb2 inverse agonist SR144528 but not by the
Cb1 inverse agonist SR141716 (Figure 3A). In contrast, the other
Cb2 ligand, CP55940, fully blocked G-CSF–induced neutrophilic
differentiation of Cb2-expressing 32D/G-CSF-R clones (Figure
3A-B). CP55940 did not affect maturation of EGFP control
32D/G-CSF-R cells (Figure 3B). Addition of Cb2 inverse agonist
to the G-CSF/CP55940–containing cultures completely restored
neutrophilic differentiation of Cb2-expressing 32D/G-CSF-R cells,
whereas the Cb1 inverse agonist had no effect (Figure 3A).
Titration experiments revealed that picomolar concentrations of
CP55940 were sufficient to significantly stimulate a differentiation
block (Figure 3C). Using 100 nM CP55940 and different concentra-
tions of Cb2 inverse agonist, we observed that neutrophilic
differentiation of Cb2-expressing cells could be recovered in a
dose-dependent manner (Figure 3D). In contrast to 2-AG, CP55940
could not induce migration of Cb2-expressing cells (Figure 3A).
CP55940-mediated block of differentiation and 2-AG–induced
migration are pertussis toxin (PTX) sensitive
Cb2 receptor belongs to the GiPCR subfamily. To study whether
Cb2 requires Gi proteins to stimulate migration or block neutro-
philic differentiation, we used PTX, a molecule that prevents
heteromer formation between the G protein and the receptor. We
observed full differentiation of Cb2-expressing 32D/G-CSF-R cells
when PTX (100 ng/mL) was added to the G-CSF/CP55940 cultures
(Figure 4A-B). Addition of PTX to the EGFP control clones had no
effect on the neutrophilic differentiation of these cells (Figure
4A-B). Moreover, 2-AG–induced migration of 32D/G-CSF-R/Cb2
cells was completely abolished by 300 ng/mL PTX (Figure 4C).
Mutation of the DRY motif in Cb2 causes a reduced migration
response to 2-AG but does not affect CP55940-mediated
block of differentiation
To assess whether the Cb2 DRY motif is important to recruit and
activate G proteins in the CP55940-mediated block of differentia-
tion and/or the 2-AG–induced migration, 32D/G-CSF-R cells were
infected with retrovirus carrying different Cb2-EGFP DRY mu-
tants. Distinct constructs (ie, Cb2-DRY [wt], Cb2-DRA mutant, and
Cb2-DAY mutant) were generated (Figure 5A), introduced into
Figure 2. 2-AG–induced migration of Cb2- or EGFP-transduced murine bone
marrow cells. Cb2-transduced (left) or EGFP-transduced (right) bone marrow
precursors were exposed to medium with or without 300 nM 2-AG. Cells were placed
in the upper well in the presence or absence of 100 nM of either Cb2 (C2) or Cb1 (C1)
inverse agonist. Data represent the mean values of 3 independent experiments. Error
bars indicate SD.
Table 1. Morphologic analysis of Cb2- and EGFP-transduced murine bone marrow cells cultured for 6 days
Experiment 1 Experiment 2 Experiment 3
Immature* Premature† Mature‡ Immature* Premature† Mature‡ Immature* Premature† Mature‡
Cb2
G§ 18 30 52 15 17 68 5 11 84
G  CP 17 39 44 29 32 39 13 30 57
G  CP  C2¶ 8 11 81 9 21 70 3 10 87
EGFP
G§ 6 11 83 17 17 66 7 6 87
G  CP 5 16 79 13 25 62 2 15 83
G  CP  C2¶ 10 20 70 7 20 73 2 8 90
*Percentage of myeloblasts and promyelocytes.
†Percentage of myelocytes and metamyelocytes.
‡Percentage of band and segmented neutrophils.
§G-CSF (100 ng/mL).
G-CSF 100 nM CP55940.
¶G-CSF 100 nM CP55940 1 M Cb2 inverse agonist.
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32D/G-CSF-R cells, and studied in transwell and differentiation
assays. Following G418 selection, 6 32D/G-CSF-R clones for each
construct were obtained. Expression of the distinct Cb2-EGFP
variants introduced into 32D/G-CSF-R cells was analyzed by
means of fluorescence microscopy and flow cytometric analysis. A
representative clone for each transfected construct is shown in
Figure 5B. Equal levels of fluorescence were detected in the 3 Cb2
clone types, and receptor membrane distribution was similar in all
cell types (Figure 5B). Binding of 2-AG and CP55940 to the
different clones was assessed by ligand binding assays. Figure 5A
indicates that receptor levels (Bmax) as well as affinities (Kd) for
2-AG and CP55940 on 32D/G-CSF-R cells were comparable
between clones transduced with the distinct constructs. Cb2
mutants cultured in the presence of G-CSF plus CP55940 showed a
block in neutrophilic differentiation (Figure 5C-D) comparable to
the differentiation block observed with the nonmutated Cb2 wt
transduced cells. This block of differentiation was reversible by the
Cb2 inverse agonist but not by addition of Cb1 inverse agonist
(Figure 5D). In contrast, the 2-AG–induced migration of 32D/G-
CSF-R/Cb2 mutants was significantly reduced in comparison with
the nonmutated Cb2 control clones (Figure 5E). The reduced levels
of 2-AG–induced migration could still be abolished by addition of
Cb2, but not Cb1, inverse agonist (Figure 5E).
dbcAMP interferes with migration but not with the neutrophilic
differentiation block of Cb2-expressing 32D/G-CSF-R cells
Because activation of GiPCRs inhibits adenyl cyclase activity, we
investigated whether down-regulation of the intracellular cAMP
levels was necessary to drive the distinct Cb2 effects. Addition of
dbcAMP, a cAMP analog, to the G-CSF plus CP55940–containing
cultures did not recover neutrophilic differentiation of 32D/G-CSF-
R/Cb2 cells (Figure 6A-B). dbcAMP did not alter neutrophilic
maturation of EGFP control clones (Figure 6A-B). Increasing
concentrations of dbcAMP partially blocked 2-AG–induced
migration of Cb2-expressing 32D/G-CSF-R cells (Figure 6C).
Thus, down-regulation of intracellular cAMP levels seems to be
partially responsible for Cb2-mediated migration but appears
unimportant for the block of neutrophilic differentiation follow-
ing Cb2 receptor stimulation.
Interference of CP55940-mediated block of differentiation
as well as 2-AG–induced migration by MEK/ERK
pathway inhibitors
We next studied whether signaling via MEK/ERK pathway is
critical for the distinct Cb2-mediated effects. MEK inhibitors,
PD98059 (Figure 6A-B) or U0126 (data not shown), fully
recovered neutrophilic differentiation of 32D/G-CSF-R/Cb2
cells cultured with G-CSF plus CP55940. MEK inhibitors did
not alter differentiation of EGFP control clones (Figure 6A-B).
Addition of U0126 to transwell assays revealed a dose-
dependent inhibition of 2-AG–induced migration of Cb2-
expressing 32D/G-CSF-R cells (Figure 6C). The same results
were observed when the cells were exposed to PD98059 in a
transwell assay (data not shown). This effect appeared highly
Figure 3. Effects of distinct cannabinoids on the G-CSF–induced neutrophilic
differentiation and migration of 32D/G-CSF-R cells. (A) Morphologic analysis of
May-Gru¨nwald Giemsa–stained cytospins of 1 representative Cb2-expressing clone
cultured in G-CSF and 100 nM 2-AG or CP55940 (CP) in the presence or absence of
1 M Cb2 (C2) or Cb1 (C1) inverse agonist. In vitro migration of 32D/G-CSF-R/Cb2
cells upon 2-AG or CP stimulation; 100 nM C2 or C1 was added to the upper well
when tested. (B) Two representative Cb2-expressing and 2 representative EGFP-
expressing clones were cultured in G-CSF and 100 nM 2-AG or CP. (C) Differential
counts of a representative CP titration experiment in the presence of G-CSF (day 8 of
culture).  indicates blast cells; f, intermediate forms; and u, terminally differenti-
ated neutrophils. (D) Differential counts of a 32D/G-CSF-R/Cb2 clone cultured with
G-CSF, 100 nM CP, and different concentrations of C2.
Figure 4. Effect of pertussis toxin (PTX) on the CP55940-evoked block of
differentiation and the 2-AG–induced migration of 32D/G-CSF-R cells. (A) Two
representative Cb2- and EGFP-expressing 32D/G-CSF-R clones were cultured for 8
days in the presence of G-CSF plus CP559940 (CP) with or without PTX (100 ng/mL).
(B) Differential counts of a representative Cb2- and EGFP-expressing 32D/G-CSF-R
clone at day 7 of culture in the presence of G-CSF with or without CP and PTX. 
indicates blast cells; f, intermediate forms; and u, terminally differentiated neutro-
phils. (C) Effect of 300 ng/mL PTX on 2-AG–induced migration of 32D/G-CSF-R/Cb2
cells. PTX was added to the cells and preincubated for 1 hour at 37°C before the cells
were placed in the upper chamber of a transwell assay. Values indicate the average of
3 representative clones. Error bars indicate SD.
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specific because stimulation of migration of 32D/G-CSF-R cells
by SDF-1, the ligand for CXCR4, could not be inhibited by
U0126 (data not shown). These data indicate that MEK/ERK
signaling is critical in 2-AG–induced migration as well as for
CP55940-induced block of neutrophilic differentiation.
Discussion
The peripheral cannabinoid receptor gene, Cb2, encodes a 7-trans-
membrane (7TM) G protein–coupled receptor (GPCR).3 Using
retroviral insertional mutagenesis, we identified Cb2 as the target
gene in the Evi11 locus, indicating that Cb2 may be a protoonco-
gene involved in leukemogenesis.1,2 We previously observed that
Cb2 is highly expressed in myeloid cell lines containing a retroviral
insertion in Cb2,1,7 and here we showed that CB2 is overexpressed
in several human myeloid leukemia cell lines. Interestingly, here
we report that CB2 is frequently overexpressed in AML blasts,
whereas normal bone marrow fractions are CB2-negative. It is
unclear why CB2 is so highly expressed in particular AML samples
and cell lines. We did not find any correlation between the different
morphologic AML subtypes and CB2 expression levels. Likewise,
no correlation was found between the origin of the distinct cell
lines and Cb2 protein levels. Real-time polymerase chain reaction
studies revealed high levels of CB2 mRNA in the CB2-positive cell
lines and not in the negative lines, suggesting altered transcription
(R.D. et al, unpublished observation, March 2003). The cause of
these differences in transcription remains to be elucidated. When
overexpressed in the myeloid precursors, Cb2 induces a block in
neutrophilic development17 and stimulates migration of Cb2-
expressing cells in vitro.7 The endocannabinoid 2-AG is the most
potent agonist capable of inducing migration of cannabinoid
receptor–expressing cells.7,9-11 Here we report that 2-AG has no
effect on the G-CSF–induced differentiation of 32D/G-CSF-R/Cb2
cells in vitro, whereas another well-described ligand, CP55940,22,23
stimulates a neutrophilic differentiation block. The fact that the
Cb2 inverse agonist SR144528 could fully counteract the 2
functions demonstrates receptor specificity. To our knowledge this
is the first example of a GPCR that, when overexpressed in myeloid
precursors cells, causes 2 different effects depending on the ligand.
Normal murine bone marrow precursors aberrantly expressing
Cb2 show a moderate but steady impairment of maturation when
cultured with G-CSF plus CP55940. Leukemia is a multigenic
disease, meaning that a combination of genetic defects is required
to obtain a full leukemia.15,16 For instance, we previously demon-
strated that aberrant Cb2 expression frequently coincides with
aberrant expression of Evi1,36,37 another transforming gene shown
to be involved in impairment of neutrophilic development.38-40 The
observation that in 32D/G-CSF-R cells Cb2 overexpression causes
a complete block of neutrophilic differentiation most likely reflects
Figure 5. Mutation of the DRY motif in Cb2 and analysis of 32D/G-CSF-R/Cb2 mutant clones. (A) Location of the DRY motif in Cb2. Introduced mutations are indicated in
bold. The box shows the results of ligand binding assays. The dissociation constant (Kd) is expressed for CP55940 in picomolars and for 2-AG in nanomolars. Maximum binding
(Bmax) is expressed as femtomoles per milligram of protein. Data were pooled from independent experiments performed on 2 clones of the same cell type. (B) Flow cytometric
analysis of representative 32D/G-CSF-R clones expressing the distinct constructs. The insets show cell fluorescence distribution in the infected cells by microscopy; original
magnification  63. (C) Four representative mutant clones cultured for 8 days in the presence of G-CSF with or without CP (100 nM). (D) Four representative 32D/G-CSF-R
clones expressing Cb2 mutants cultured in G-CSF with or without CP, Cb2 (C2), and Cb1 (C1) inverse agonist (100 nM). Counts were carried out on day 8 of culture. 
indicates blast cells; f, intermediate forms; and u, terminally differentiated neutrophils. (E) In vitro migration of cells containing a DRY, DRA, or DAY motif. Cells were exposed
to medium with 300 nM 2-AG or control medium; 100 nM C1 or C2 was added to the upper chamber.The percentage of migration is the average of 3 clones.
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cooperation between Cb2 and other genetic defects present in this
myeloid precursor cell line. Interestingly, Evi1 retroviral insertions
as well as overexpression have been reported for 32D cells.41 It
would be of interest to study whether overexpression of Cb2 in
combination with Evi1 in normal marrow precursors would lead to
a more severe block of neutrophilic differentiation.
The experiments presented in this paper demonstrate that Cb2
receptor may evoke 2 distinct biologic effects depending on the
ligand used for stimulation (ie, migration upon 2-AG presentation
and block in neutrophilic differentiation following exposure to
CP55940). How the interaction of distinct Cb2 ligands to Cb2
receptor may result in activation of different processes in the same
cell is an interesting question. Several examples exist of one
receptor interacting with distinct ligands. The cytokines IL-3, IL-5,
as well as GM-CSF interact with different receptor complexes that
all share a common  receptor chain. The specificity of these
distinct ligands for the different complexes is determined by the
ligand-specific receptor  chains.42,43 Similarly, IL-2, IL4, IL-7,
IL-9, and IL-15 each interact with unique receptor complexes that
all share a common  chain.44,45 The distinct effects that we
observed upon 2-AG or CP55940 stimulation may be explained by
stimulation of 2 distinct receptor complexes that both contain the
Cb2 receptor. For a long time it was generally believed that GPCRs
function as monomers. However, GPCRs may be involved in
high–molecular weight complexes formed by homodimers as well
as heterodimers. Interestingly, dimer formation may affect receptor-
ligand binding, signaling, and function.46-48 Another intriguing
observation is that agonist presentation can promote or decrease
receptor dimerization in several GPCRs.49-51 In addition, receptor
heterodimerization between GPCRs may result in generation of
novel ligand binding sites52 or novel ligand binding properties.53
GPCRs may even interact with non-G protein–coupled receptors,
such as tyrosine kinase receptors.54 In this respect it is interesting
that a functional interaction between CB1 receptor and fibroblast
growth factor receptor as well as with the insulin-like growth factor
1 receptor has been demonstrated.55,56 Our observation that binding
of distinct ligands to Cb2 receptors evoked different effects may be
explained by the Cb2 receptor being present in distinct complexes
depending on the ligand or acting as a monomer with one agonist
and as a dimer or multimer with the other.
Cb2 belongs to the family of GPCRs,3,57,58 suggesting that
signaling upon receptor stimulation may require G proteins. The
inhibition of migration by PTX administration, as well as the
inefficient chemotaxis of cells expressing DRY-Cb2 mutants,
indicates that Cb2 receptor requires G protein activity to induce
migration upon 2-AG stimulation. In addition, most chemokine
receptors belong to the subgroup of GiPCRs,59-61 suggesting that
adenyl cyclase inactivation and cAMP down-modulation via Gi
proteins may be critical for induction of migration. The decrease of
2-AG–induced migration of 32D/G-CSF-R/Cb2 cells following
dbcAMP administration demonstrates that this pathway is critical
for Cb2-mediated cell motility. On the other hand, our data show
that down-regulation of the intracellular cAMP levels is not the
only pathway involved in migration of Cb2-expressing cells.
Transwell studies using MEK inhibitors demonstrate that this route
plays a critical role in 2-AG–stimulated chemotaxis as well.
Previous studies demonstrated that stimulation of cannabinoid
receptors Cb1 and Cb2 causes phosphorylation of ERK and,
consequently, activation of this pathway.62-64 Although critical for
Cb2-induced chemotaxis, MEK/ERK signaling is not a prerequisite
for GPCR-induced migration in general. For instance, SDF-1–
induced migration of 32D/G-CSF-R/Cb2 cells that endogenously
express CXCR4 receptor is insensitive to the addition of MEK
inhibitors (data not shown). We clearly demonstrate that the
2-AG–induced migration involves MEK/ERK pathway, but the
mechanism of activation remains unclear. Multiple examples show
that the MEK/ERK signaling route may be activated through the
 complex,65 although G protein–independent manners of ERK
activation have been proposed as well for GPCRs.65,66 Summariz-
ing, Cb2-mediated migration depends on at least 2 distinct
signaling pathways that both appear to be indispensable (Figure 7).
As with migration induction, our data suggest that multiple
pathways are involved in the Cb2-induced block of differentiation
(Figure 7). MEK/ERK signaling has been shown to be critical,
because MEK inhibitors fully recovered G-CSF–induced differen-
tiation in the presence of CP55940. Previously, we also demon-
strated involvement of phosphatidylinositol-3 kinase (PI-3K) in the
Figure 7. Schematic representation of Cb2 signaling. Signal transduction path-
ways linked to Cb2 leading to the 2-AG–induced migration and the CP55940-evoked
block of neutrophilic differentiation.
Figure 6. Effects of dbcAMP and MEK/ERK inhibitors on 2-AG–induced
migration and the CP55940-stimulated block of differentiation. (A) A representa-
tive Cb2 and EGFP control 32D/G-CSF-R clone cultured with G-CSF with or without
100 nM CP55940 (CP), 100 M dbcAMP, or 25 M PD98059 (PD). (B) Pictures of
May-Gru¨nwald Giemsa–stained cytospins (day 8) of a representative Cb2-
expressing 32D/G-CSF-R clone cultured under the different conditions. Original
magnification  63. (C) Effects of different concentrations of dbcAMP and U0126 on
the 2-AG–induced (300 nM) migration of a representative Cb2-expressing 32D/G-
CSF-R clone. The y-axis indicates the percentage of migrated cells in relation to the
nontreated cells.
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Cb2-mediated block of differentiation.17 On the other hand,
intracellular cAMP down-regulation is unimportant for this effect.
Moreover, the DRY motif, which is critical for the 2-AG–induced
migration, was completely unnecessary for the induction of a
maturation arrest. These experiments would suggest that G protein
signaling is dispensable for the Cb2-induced differentiation block.
However, we demonstrated that the CP55940-evoked block in
differentiation of 32D/G-CSF-R/Cb2 cells could be fully reversed
by the addition of PTX. Therefore, these data suggest that activated
Cb2 receptors may induce the proper signals via G proteins, but
because we observed that the DRY motif is unnecessary for the
CP55940-induced block of differentiation, we suggest involvement
of another currently unknown G protein interaction domain in Cb2.
Multiple GPCRs have previously been reported to have trans-
forming abilities—for example, the 1B-adrenergic,67 thrombin,68
and serotonin 1C receptors69 and the receptor encoded by the Mas
oncogene.70,71 In contrast to Cb2, which interacts with Gi subunits,
many of these previously identified transforming GPCRs can
associate with Gs subunits.72 An interesting question is whether
transformation of myeloid precursor cells by Cb2 is a feature
unique for this particular GPCR or whether the peripheral cannabi-
noid receptor is a paradigm for a novel class of transforming
GPCRs. The fact that we have shown that stimulation of migration
as well as the interference with differentiation by Cb2 are PTX
sensitive, meaning involvement of Gi, may indicate that other
Gi-interacting GPCRs with transforming abilities may exist.
Interestingly, using retroviral insertional mutagenesis, we and
others recently identified, among a large panel of novel leukemia
disease genes, 4 GPCR-encoding genes (Suzuki et al73; Joosten et
al74; and R.D. et al, unpublished observation, November 2002).
Three of those genes encode GPCR that may interact with Gi
subunits: endothelial differentiation gene 3-R (Edg3-R), chemo-
kine-R7 (CCR7), and vomeronasal1-R (V1-R). Introduction of
these transforming receptors or other potentially interesting GPCRs
into 32D/G-CSF-R cells will be a valid approach to determine
whether Cb2 is a paradigm for a novel class of transform-
ing GPCRs.
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